The interview includes basic information about the business plan of Vitro Biopharma, including size of the markets being targeted, competitive advantages of the product offering, strategic alliances and the near term prospects for Vitro Biopharma.

During the interview, Dr. Musick stressed that diversified sources of revenue for Vitro Biopharma position the Company for future success and improve long-term shareholder value. While current revenues are derived from sales of stem cell tools for research and clinical development, additional and more substantial markets are being pursued in drug discovery, development and toxicology together with select markets in regenerative medicine. The latter includes stem cell therapeutic products targeting soft tissue and joint injury & disease in dogs and horses. Vitro Biopharma also owns patented technology for the production of Follicle-stimulating hormone, which is commonly used to treat infertility, a substantial and well-established, multi-billion dollar global market. In 2011, Vitro Biopharma out-licensed this technology through an agreement that includes royalty payments from product sales, thus providing an additional potential source of revenue.

Contributed by Jim Musick, Ph.D., President and CEO of Vitro Biopharma.

The post Vitro Biopharma CEO Interviewed by Wall Street Ledger appeared first on Vitro Biopharma.

Golden, Colorado—February 20, 2013—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, simultaneously accepted the resignation of Mr. Erik Van Horn from its Board of Directors and appointed Pete Shuster, the CEO of Neuromics, Inc. to its Board of Directors.  Mr. Shuster is a seasoned and experienced sales executive.  He is the current owner of Neuromics, Inc., a privately held and profitable business focused on sales of numerous (>2500) specialty life science products including stem cell products manufactured by Vitro Biopharma.  Neuromics, Inc. sales have grown over 5.5-fold since inception in 2003.  Shuster has extensive prior experience in managing sales of computer software and related products for companies including Caterpillar, Baxter Healthcare and Harley-Davidson.

Mr. Erik Van Horn has also resigned from Vitro Biopharma’s Board of Directors due to the request of his present employer.  Vitro Biopharma is presently engaged in expansion of sales of its stem cell products and is executing a marketing and distribution strategy based on strategic expansion of its product lines together with accelerated sales activity.  Thus, while the Board regrets the loss of Mr. Van Horn’s management expertise and technical acumen, its present business development activities are considerably strengthened through the addition of Mr. Shuster to its Board of Directors.

Dr. Jim Musick, Vitro Biopharma’s President & CEO, said, “I am very pleased to have been associated with Mr. Erik Van Horn throughout his tenure with Vitro Biopharma.  Erik joined Vitro Biopharma in 1991 as an employee and was instrumental in the establishment of the diagnostic antigen business unit that was later sold to Venaxis,Inc., formerly Aspen Biopharma, Inc. (Nasdaq, APPY).  He subsequently contributed to the technical development of our present stem cell product line while providing critical business guidance throughout his role as a director of the company. On behalf of all Vitro Biopharma shareholders, stakeholders and other associates, I congratulate Erik on his contributions and service to the Company.  I am also very pleased to announce the addition of Mr. Pete Shuster to the   Board of Directors.  His strong background in sales of similar products to those that we manufacture represents a significant addition to our team.  I greatly look forward to working more directly with Mr. Shuster to advance our business plan focused on expansion of sales of existing products and strategic addition of new high-value products to enhance drug discovery and development through use of well-characterized cell-based assay systems derived from stem cell technology and through the introduction of novel products targeting select opportunities within the field of regenerative medicine.”

“Jim Musick and his team have developed an innovative platform for generating umbilical cord blood and induced pluripotent derived stem cells”, said Shuster.  “They are well positioned to provide both off the shelf and engineered cells to align with the unique needs of pharmaceutical and biotech companies in discovering new therapies for autoimmune and degenerative diseases as well as certain forms of cancer. I look forward working closely with Jim to generate profitable revenue from his current and future stem cell based assay solutions.”

There are currently no commitments or understandings regarding Mr. Shuster’s compensation as a director, although it is expected he will be offered some form of equity package consisting of stock options, stock grants or a combination.  No decision has been made with respect to Mr. Shuster’s service on one or more standing committees of the Board.

About Mr. Pete Shuster

He received a Bachelor’s Degree in Biology from Lawrence University in Wisconsin during 1981 and performed graduate studies in biochemistry at the University of Minnesota.  He was in Sales and Sales Management with Teltech from 1985 to 1994 where he was a top producer.  He was a sales representative at Connect, Inc from 1994 to 1995 where he sold systems integration solutions. He was a Major Account manager at SDRC from 1995 to 1999 and Senior Account Manager at EAI for sales of Product Visualization Software.  At both of these firms, he achieved significant sales success including completion of several large transactions. In 1998, he was recognized as the #1 sales person worldwide for total sales of Metaphase Product Data Management solutions with multi-million dollar sales to Harley Davidson, Baxter Healthcare and Sauer Sundstrand.  From 1996 to 2002, he was the founder and owner of Kingdom2.com, an online reseller of re-manufactured satellite systems. From 2000 to 2002 he was Large Account Sales Director of PTC, a company that sold product data management and CAD software, where he lead teams that sold  to heavy equipment manufacturers, including Caterpillar, John Deere and Case. The team achieved sales > $15,000,000 in FY2001.

In 2003, he founded Neuromics, Inc, his present business that is a web-based marketer of reagents to accelerate discovery in Neuroscience, Diabetes/Obesity and Cancer offering products including antibodies, proteins, transfection reagents, stem cell and primary cell lines, cell culture media and apoptosis measurement kits.  He maintains a strong presence in various social media and is responsible for several blogs related to life science products.  He has considerable expertise and experience in strategic selling.

About Vitro Biopharma

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes.  In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies.  Vitro Biopharma also owns a pending US patent for generation of pluripotent stem cells and an additional pending patent for methods of mesenchymal stem cell (MSC) generation and related materials. Vitro Biopharma’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado.  Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation.  In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (www.neuromics.com).  Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems We jointly manufacture stem cell assay systems with HemoGenix^®, Inc. (http://www.hemogenix.com/), known as the LUMENESC™ quantitative assay for determination of MSC quality, potency and response to toxic agents.  Vitro Biopharma has an agreement with Stemgenesis, Inc. (http://www.stemgenesisinc.com) for distribution of its stem cell products into select Chinese provinces.  Also, Vitro Biopharma’s CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission.  Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

Source: Vitro Diagnostics, Inc.

The post Vitro Biopharma Appoints Sales Executive to its Board of Directors appeared first on Vitro Biopharma.

The researchers engineered mice MSCs to express insulin-like growth factor-1 (IGF-I) then transplanted the treated cells into mice with non-union fractures. Computed tomography scanning showed that the mice treated with MSCs expressing IGF-I experienced faster healing than the control group and the mice treated with only MSCs. The new bone was shown to be three or four times stronger, and more bone bridging the fracture gap than the control group.

A similar study was done by Dr. Richard Kremer at McGill University Health Care. First, mesenchymal stem cells were cultured to turn into osteoblasts in-vitro and it was found that the differentiation process involved interferon (IFN) gamma-related genes [2]. In order to study the involvement of IFN gamma-related genes, they moved to an animal model where the IFN gamma effect was blocked by inactivating its receptor. Blocking this effect caused significantly lower bone mass than their healthy counterparts. Their MSCs also showed a decreased ability to make bone, confirming that IFN gamma is an integral factor for MSCs differentiation into osteoblasts. These findings suggest that IFN gamma, or another molecule involved in its pathway could become a treatment for osteoporosis.

Researchers from the University of California, Davis Health System have engineered a molecule, LLP2A-alendronate, that when injected into the bloodstream prompts indigenous stem cells to travel to the surface of bones and differentiate into osteoblasts [3]. LLP2A-alendronate is a hybrid molecule that consists of the LLP2A part that attaches to the MSCs in the bone marrow, and a second part that consists of the bone-homing drug, alendronate [4]. This molecule was tested on mice and showed evidence of reducing the signs of osteoporosis, holding major promise for the development of new drugs to treat this disease. This technique directs a person’s endogenous MSCs to the bone surface so that they can regenerate bones.

MSCs can be used to speed the healing of non-union fractures and strengthen bones through the use of different protein signals and molecules. The most effective way to signal MSCs to repair bones is currently undergoing research. These studies show potential for the development of new drugs to treat osteoporosis.

Vitro Biopharma has recently launched its initial line of osteoblasts derived from human MSCs for use in drug discovery and development. These products enable researchers to conduct various cellular assays to assist in development of novel therapies of bone degenerative diseases and accelerated recovery of fractured bones.

Contributed by Lianne Nelsen, Research Technician, Vitro Biopharma & Chemical Engineering student at the Colorado School of Mines.

[1] Lang, Les. 6 Jun 2011. “Stem cell treatment may offer option for broken bones that don’t heal.” Web.  <http://www.med.unc.edu/www/newsarchive/2011/june/stem-cell-treatment-may-offer-option-for-broken-bones-that-don2019t-heal>

[2] “Stem cells could halt osteoporosis, promote bone growth MUHC team describes a new pathway that controls bone remodeling.” 4 Mar 2009.  Web. <http://muhc.ca/newsroom/news/stem-cells-could-halt-osteoporosis-promote-bone-growth-muhc-team-describes-new-pathway-controls>

[3] “Study uses stem cells to treat osteoporosis.” Web.  <http://www.canadianpharmacymeds.com/news/study-uses-stem-cells-to-treat-osteoporosis–800702652>

[4] “UC Davis investigators develop method of directing stem cells to increase bone formation and bone strength.” 6 Feb 2012. Web. <www.ucdmc.ucdavis.edu/publish/news>

The post Stem Cell Treatment for Bone Fractures appeared first on Vitro Biopharma.

Wound healing includes three phases: inflammatory, proliferative, and remodeling. MSCs have been found to be involved in all three phases of wound healing. MSCs have a strong anti-inflammatory response by decreasing secretion of pro-inflammatory cytokines (tumor necrosis factor-α and interferon-γ) while also increasing the production of anti-inflammatory cytokines (prostaglandin E₂) (Maxson et al., 2012). By decreasing the inflammatory phase of wound healing, MSCs can restart healing in chronic wounds by advancing to the next stage of healing. In the proliferative phase of wound healing, MSCs’ antimicrobial activity is crucial for avoidance of infection. MSCs use paracrine signaling to secrete growth factors (vascular endothelial growth factor and hepatocyte growth factor) to help avoid scarring of the skin tissue during the remodeling phase.

A promising study has recently been published on the effects of MSCs in chronic wound healing. A group of normal and diabetic mice were given two different dermal abrasions. Mice given MSC grafts showed faster healing than those without the graft. While the diabetic mice still healed slower than the healthy ones,  MSCs increased the rate of wound healing. Also, the wound that was not treated with MSCs showed an indirect effect of MSC exposure that promoted wound healing, thus showing that MSCs recruit existing endogenous tissue cells, possibly MSCs, to enhance wound healing. The grafted MSCs were labeled with a green fluorescent protein; after 10 days of healing time, there was no trace of the green fluorescent cells in the wound or anywhere else in the body (Shin et al., 2012). The accelerated healing persisted even after the disappearance of these fluorescent MSCs, suggesting their role in signaling the recruitment and homing of endogenous cells.

Several other human clinical trials have shown that the administration of MSCs accelerate healing in chronic wounds. In a study of chronic diabetic foot ulcers, the size of the ulcers decreased and dermal thickness improved following the injection of MSCs into the edges of the wounds. Another study involved treating 20 patients with various chronic non-healing wounds with autologous bone marrow derived MSCs. Treatment with a cellular  graft, composed of MSCs & fibrin, produced complete healing of 90% of the wounds. (Maxson et al., 2012).

One of the limitations to MSC wound healing therapy is the method of delivering the cells; to administer the cells locally, an appropriate carrier or scaffold is required.  Fibrin spray or a fibrin sealant enriched with MSCs is often used.  These therapies repair excisional wounds by decreasing the time required for re-epithelialization (Jackson et al., 2011). Further studies are needed to elucidate the interactions between MSCs and immune and wound healing cell types that are present in the wound bed in order to find the most effective mode of delivery and how to utilize these MSCs for wound healing.

Vitro Biopharma is now developing a MSC-based wound healing product and plans animal testing of this product in the near future.

Contributed by Lianne Nelsen, Research Technician at Vitro Biopharma & Chemical Engineering student at the Colorado School of Mines.

References:
Jackson, W. M., Nesti, L.J., and R. S. Tuan. 7 Dec 2011. “Concise Review: Clinical Translation of Wound Healing Therapies Based on Mesenchymal Stem Cells.” SCTM (Stem Cells Translational Medicine) Express.

Maxson, S., Lopez, E.A., Yoo, D., Danilkovitch-Miagkova, A., and M. A. LeRoux. 6 Feb 2012. “Concise Review: Role of Mesenchymal Stem Cells in Wound Repair.” SCTM Express.

Shin, L., And D. A. Peterson. 21 Dec 2012. “Human Mesenchymal Stem Cell Grafts Enhance Normal and Impaired Wound Healing by Recruiting Existing Endogenous Tissue Stem/Progenitor Cells.” SCTM Express.

The post Enhanced Wound Healing by MSCs appeared first on Vitro Biopharma.

Golden, Colorado—January 22, 2013—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs.  The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs).  These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures.  Osteoporosis, a disease characterized by reduction in bone density is thought to result from decreased osteoblast production by MSCs; bone growth necessary for repair of bone fractures also depends on osteoblasts. The new products include native and labeled MSC-derived human osteoblasts in various formats including fluorescent and magnetic cells for use in different imaging methods.  For example, magnetic osteoblast cells labeled with super paramagnetic iron oxide (SPIO) may be used for in-vivo imaging of osteoblasts using magnetic resonance imaging (MRI) a common clinical imaging procedure. The availability of native and multiply-labeled osteoblasts provides numerous options to conduct in-vitro high throughput screening cell assays and to coordinate these studies with in-vivo studies. 

Dr. Jim Musick, Vitro Biopharma’s President & CEO, said, “We are pleased to announce commercial availability of our MSC-derived human osteoblasts, the latest in our line of MSC-derived differentiated cells intended for applications in drug discovery and development as well as regenerative medicine.  Diseases and injury to the skeletal system pose significant health risk and impairment of function.  The incidence of osteoporosis continues to rise with the aging population.  Bone fractures are common injuries requiring long healing times and significant loss of production.  Improved treatment of osteoporosis and accelerated recovery from bone fractures both provide significant health benefits.  We are pleased to offer our new products to assist in the achievement of these objectives.  We have additional related products in our pipeline and plan to engage in animal studies in the near future to determine the application of our new products to accelerated healing and regenerative medicine.” 

About Vitro Biopharma  

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes.  In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies.  Vitro Biopharma also owns a pending US patent for generation of pluripotent stem cells and an additional pending patent for methods of mesenchymal stem cell (MSC) generation and related materials. Vitro Biopharma’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado.  Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation.  In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (www.neuromics.com).  Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems We jointly manufacture stem cell assay systems with HemoGenix^®, Inc. (http://www.hemogenix.com/), known as the LUMENESC™ quantitative assay for determination of MSC quality, potency and response to toxic agents.  Stemgenesis, Inc. (http://www.stemgenesisinc.com ) is a Chinese-based firm with operations in Qingdao, Shandong Province, China and with US operations in Sacramento, CA.  Vitro Biopharma has an agreement with Stemgenesis, Inc. for distribution of its stem cell products into select Chinese provinces.  Also, Vitro Biopharma’s CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells. 

Safe Harbor Statement 

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission.  Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise. 

CONTACT:

                  Dr. James Musick

                  Chief Executive Officer

                  Vitro Biopharma

                  (303) 999-2130 Ext. 3

                  E-mail: jim@vitrobiopharma.com 

Source: Vitro Diagnostics, Inc.

The post Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth appeared first on Vitro Biopharma.

I met Lane Gilchrist, Ph.D., at a Keystone Scientific Symposium in 2010 concerning technology related to induced-pluripotent stem cells. Recently, Drs. Gurdon and Yamanaka received the 2012 Nobel Prize in Physiology or Medicine for their pioneering work in the discovery of methods to genetically reprogram adult cells to achieve pluripotency (the ability to differentiate into any cell type). Lane and I both share the vision for the crucial role of extracellular matrix materials in stem cell functioning. Recently, Dr. Gilchrist and a team of scientists at the City College of New York (CCNY) where Lane is a Professor of Chemical Engineering and Biomedical Engineering, received funding of a grant entitled “Biomimetic Ligand Display in Proteolipid Hybrid Matrices to Direct Stem Cell Chondrogenesis” from the National Science Foundation. The co-investigators included Steve Nicoll (CCNY BME: Biomaterials for tissue engineering), Raymond Tu (CCNY ChE-Biomolecular engineering) and Sihong Wang (CCNY BME-Biomedical microdevices in cellular engineering). The grant is for a three-year period and I am a consultant on this grant. Thus, I will be providing consultation related to the biological aspects of the effects of bioengineered materials on the functional/clinical properties of stem cells. I am very pleased to be assisting the CCNY team to achieve their goals. Also, since Dr. Gilchrist and I realize the central role of extracellular matrices on stem cell function, we are working to expand our collaboration to include additional technology/product developments with perceived commercial impact on the clinical development of stem cell-based therapies.

Dr. Gilchrist said, “Dr. Musick and I share interests and a passion for contribution to the evolution of stem cell technology to its full potential. I look forward to working with Dr. Musick on our grant and furthermore, in subsequent commercialization of products based on novel, bioengineered scaffolds which mimic the native niche environment of stem cells.”

Contributed by: Jim Musick, Ph.D. President and CEO of Vitro Biopharma/Vitro Diagnostics, Inc.

The post Stem Cell Culture Depends on Extracellular Materials: Vitro Biopharma Expands its Collaboration with CCNY Researchers to Develop Novel Cell Culture Materials appeared first on Vitro Biopharma.

December 11, 2012

Golden, Colorado—December 11, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the following open letter to its shareholders:

Dear Fellow Shareholders:

I am pleased to report our progress during 2012 including significant advances in our business focused on the development, manufacture and commercial distribution of essential tools to support adult stem cell research and clinical development.

The highlights of our achievements in 2012 include: 

• A new and improved website featuring E-commerce of our products, expanded technical and investor relations information and utilization of social media to expand awareness of the Company and its products.
• Establishment of distribution of our products through Neuromics, Inc., a privately held firm in Minneapolis, MN focused exclusively on sales of a variety of products to support life science research.
• Attendance and technical presentation at the International Society for Cellular Therapy Annual meeting resulting in increased collaborative opportunities and product sales.
• Establishment of a distribution agreement with Stemgenesis, Inc. for the exclusive distribution of our products into select Chinese Provinces.
• Launch of new products with application to enhancement of cellular therapy of articular (joint) diseases and injury & filing of a US Patent application to expand our near-term product pipeline.
• Continued support and business development by our FSH patent licensee resulting in advancements in fertility drug manufacturing, distribution and regulatory approvals for treatment of human infertility, a multi-billion dollar global market that continues to expand.

There is more detail about these events published on our website: www.vitrobiopharma.com.

A key advancement that occurred in 2012 was increased product distribution leading to increased revenue generation.  We have previously demonstrated significant competitive advantages of our MSC-Gro™ Brand of cell culture media optimized for mesenchymal stem cell (MSC) growth and differentiation, including increased cell growth, cellular recovery and shelf-life.  While sales of this product line developed more slowly, I am now pleased to announce that sales of our lead MSC-Gro™ product (Low-serum complete MSC-Gro™ medium) have grown substantially since commercial introduction including a 114% increase in sales during 2012 compared to 2011 and a 9.5-fold increase in the early stages of our 1^st quarter 2013 compared to the entire 1^st quarter 2012.  Sales of our other MSC-Gro™ media products and MSC-based cell lines have also increased. Our

Annual report for 2012 is currently underway and we will report 2012 earnings as this report is filed with the SEC.  I attribute increased distribution of our products to our competitive advantages, recognition of product quality by customers and increased awareness of these products through our improved website and distribution partnerships.

Our primary corporate objective is the attainment of profitability and earnings growth.  With the platform now established, our operations are focused on increased manufacturing capacity to maintain appropriate inventories to support increased product sales.  We are now adding needed human resources, equipment and raw materials to serve our customers as rapidly as possible and to continue our marketing program to enhance awareness of our products and technology to our global markets.  Our management team is seasoned and experienced in the issues faced by a growing biotechnology operation and provides superior guidance to support our growth.  We are also committed to the expansion of our product lines to expand revenue opportunities.  For example, we have recently added human chondrocytes derived from human MSCs and plan additional new products.  Chondrocytes produce collagen and are essential to the function of joints.  Stem cell therapy of injured or diseased joints is a very active area of clinical research that shows pre-clinical support of safety and efficacy of MSC-based therapy.  Thus our new products provide important tools to advance cell therapy of injury, diseases and regeneration of joints. MSC therapy may eventually be developed to allow for regeneration of injured or diseased joints, without the necessity of using artificial joints. We plan to launch additional new products during 2013 to support and sustain our revenue growth.

While our initial products target research use, we are also expanding our offerings to include products with clinical application.  We now have select MSC-Gro™ products with clinical application and intend to strengthen these products in 2013 through appropriate regulatory filings with the FDA.  It is especially important that cell culture media products do not contain human or animal serum and are chemically defined to minimize potential contamination of cultured cells that are subsequently administered to patients to test for clinical benefit.  This, serum-free, chemically defined media is classified as a medical device and requires much less time and money to achieve FDA approval than new drugs or biologics. Approval of a medical device typically requires less than one year and only laboratory testing while drugs and biologics can require 8-10 years, extensive clinical trial testing and cost $0.5 to $1 billion to gain approval, which is not guaranteed. We are also developing cellular products targeting therapeutic veterinary applications.  Furthermore, through our interactions with local physicians, we are exploring additional clinical applications of our products and technology.

It is also important to recognize that our capital structure and expenses are well suited the attainment of profitability and earnings growth.  Management has pursued its corporate development without requiring extensive outside capital and resultant dilution of shareholders.  Hence, we have less than 20 million shares outstanding, relatively modest expenses and high gross profit margins.  We are thus well positioned for rapid turn-around and earnings growth.   Since the sale of our diagnostic operations in 2000, I have personally contributed substantially, both financially and in development of our products and technology, to our corporate development and remain firmly committed to the achievement of solid financial performance of Vitro Biopharma.

I greatly appreciate the support provided by our shareholders and look forward to continued progress in the development of our business.  We are also privileged to work in the field of adult stem cell technology where there are substantial opportunities to develop new treatments of significant diseases and injuries and to also contribute to the advancement of regenerative medicine.

Sincerely yours,

James R. Musick, Ph.D.

President, Chairman of the Board and CEO

Safe Harbor Statement 

Certain statements contained herein and subsequent oral statements made by and on behalf of the Company may contain “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission.  Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to publicly update these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:    Dr. James Musick

                        Chief Executive Officer

                        Vitro Biopharma

                        (303) 999-2130

                        E-mail: jim@vitrobiopharma.com

_______________________

Source: Vitro Diagnostics, Inc.

The post Vitro Announces Open Letter to Its Shareholders: appeared first on Vitro Biopharma.

Nanotechnology is based on use of extremely small materials (<100 nanometers or 1/10 of a micrometer) whose properties change at these minute sizes. This enables several advances in medical applications including targeted drug delivery, imaging, detection of specific events, and transfer of biologically active substances into cells. Several other applications are being pursued and it is possible that nanotechnology will eventually revolutionize medicine. The application of nanotechnology to stem cell technology opens additional opportunities to expand the capacity of stem cell technology to advance medicine. We have recently utilized methods to transfer nanoparticles into stem cells to provide advanced capabilities to detect stem cells within the body through in-vivo imaging.

We are now using magnetic, iron-containing nanoparticles to label stem cells for imaging by magnetic resonance imaging(MRI). The figure shown at the upper left shows the presence of iron-containing nanoparticles within human MSCs. (The image is 200X phase contrast following iron staining by Prussian Blue stain; dark deposits indicate iron presence.)  We are now optimizing the method for delivery of iron-containing nanoparticles to cells prior to commercial launch of new products.

MSCs labeled with iron-containing nanoparticles may be detected using clinical MRI instrumentation allowing visualization of stem cells and migration to particular targets. For example, it is known that MSCs migrate to cancer stem cells so there is a potential application of these labeled MSCs in cancer diagnostics. Also, genetically engineered MSCs are now being investigated for potential cancer therapies that target cancer stem cells and then deliver toxic substances. In most clinical applications of stem cells, in-vivo imaging of stem cells is desirable. We plan to expand our in-vivo imaging products to include multiple labels of stem cells allowing more complete in-vivo imaging analysis of stem cells.

Contributed by: Jim Musick, Ph.D. President and CEO of Vitro Biopharma/Vitro Diagnostics, Inc.

The post Nanotechnology Offers New Opportunities to Enhance Stem Cell Technology: Application to In-Vivo Imaging appeared first on Vitro Biopharma.

Pete Shuster, CEO of Neuromics, said, “We are pleased to add Vitro Biopharma’s MSC-derived chondrocytes to our expanding line of cells for use in cell-based assays. We see a continual need for these products to fuel accelerating research by pharmaceutical and biotechnology firms to expand product pipelines. The promise of stem cell-based regenerative medicine is also supported by stem cell-derived products suitable for in-vivo imaging that may be then correlated with clinical measurements of efficacy.”

Dr. Jim Musick, Vitro Biopharma’s President & CEO, said, “We are pleased to announce commercial availability of our MSC-derived human chondrocytes. These products offer numerous competitive advantages including consistent and well-defined cellular characteristics, multiple forms including native, fluorescent and SPIO-labeled that are suitable for numerous applications in current drug development, discovery and toxicology together with applications in joint regeneration research. There are several debilitating joint diseases such as arthritis, osteoarthritis together with common injury to joints in both humans and animals. We intend to support the development of new, modern treatments of these conditions with these products. We plan further extensions of these products including clinical products and additional stem cell derived cells for use in drug discovery and development together with animal cells. We are presently developing MSC-derived endothelial cells and osteoblasts for use in the development of advanced treatments of cardiovascular and orthopedic diseases.”

About Neuromics, Inc.

Neuromics (http://www.neuromics.com), located in Minneapolis, MN, is a profitable and growing bio-reagents company. The company was initially built by supplying bio-markers to Neuroscience Researchers. Today, Neuromics provides a range of solutions that include markers, growth factors, gene expression analysis tools, apoptosis detection kits, primary cells and related media. These solutions are increasingly being used in combinations by customers to help accelerate or improve the process of drug discovery.

About Vitro Biopharma

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG; http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. In 2011, Vitro out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies. Vitro also owns a pending US patent for generation of pluripotent stem cells and an additional pending patent for methods of mesenchymal stem cell (MSC) generation and related materials. Vitro’s mission is “Harnessing the Power of Cells(TM)” for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development(TM)”, including human mesenchymal stem cells and derivatives, the MSC-Gro(TM) Brand of optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro formed a strategic alliance with HemoGenix(R), Inc. (http://www.hemogenix.com/) to jointly manufacture and distribute the LUMENESC(TM) quantitative assay for determination of MSC quality, potency and response to toxic agents.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

The post Vitro Biopharma Launches Products for Drug Development & Advancement of Joint Regeneration Technology appeared first on Vitro Biopharma.